

Activity Outline
Topics in Public Health: Managing Logistics and Roles for Treatment and Prevention of COVID-19
July 22, 2022
Webinar

Activity Coordinators:

Amy Ramanadham (Amy.Ramanadham@fda.hhs.gov), Jessica Voqui (jessica.voqui@fda.hhs.gov)

Series Description

This series will educate PHS health professionals about topics that are pertinent to their roles within the various agencies within the Department of Health and Human Services and other Public Health Service agencies by presenting topics that directly relate to the HHS Strategic Plan, the Secretary's Strategic Initiatives, current topics for DHHS OPDIVs who utilize PHS health professionals, and/or other topics directly related to the advancement of public health.

Lecture Description

While many focus on the difficulties of identifying therapeutics for treatment and prevention, a second layer of difficulty lies with the logistics of getting therapeutics to patients. This presentation will provide an overview of the various strategies that can be employed in order to quickly and effectively adapt to changing recommendations for COVID-19 therapeutics, including those for both treatment and prevention.

References

- COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at <https://www.covid19treatmentguidelines.nih.gov/>. Accessed 9 Jun 2022.
- Use of COVID-19 Vaccines in the United States. Interim Clinical Considerations. Centers for Disease Control and Prevention. Available at <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>. Accessed 9 Jun 2022.

Series Objectives

- Increase awareness of current topics in public health
- Help improve patient/public health outcomes
- Help participants modify their practice within their job or deployments

Learning Objectives After completion of this activity, the participant will be able to:

- Describe the strategies employed by the Phoenix Indian Medical Center during the COVID-19 pandemic for disease treatment and prevention
- Adapt strategies utilized during the pandemic to other public health concerns
- Evaluate the role of the pharmacist for future public health crises

Target Audience

This activity is intended for physicians, pharmacists, pharmacy technicians, nurses, This activity is intended for physicians, pharmacists, nurses, and other public health medical professionals interested in learning more about the initiatives other advances in public health..

Agenda

Lecture 1 July 22, 2022

| TIME | TOPIC | SPEAKER |
|--------------------|---|--------------------------|
| 2:00 - 3:00 PM EDT | Managing Logistics and Roles for Treatment and Prevention of COVID-19 | Abigail Petrulis, PharmD |

Continuing Education Accreditation



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



IPCE CREDIT™

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

CME

FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE

This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-22-026-L04-P, and ACPE Universal Activity Number JA0002895-0000-22-026-L04-T for 1.00 contact hour(s).

CNE

FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).

CPH

Up to 1.00 CPH Recertification Credits may be earned at this event.

Requirements for Receiving CE Credit

Physicians, pharmacists, nurses, pharmacist techs, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.

Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.

Important Note regarding completion of evaluations and receiving credit

Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit. Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.

Disclosure

Faculty

- Petruľis, Abigail, PharmD, Immunization Director, Indian Health Service - *nothing to disclose*

Planning Committee

- BIRCH-SMITH, POSTELLE, PharmD - *nothing to disclose*
- Brodhead, LeAnn, PharmD, Health Insurance Specialist, CMS - *nothing to disclose*
- Januszewicz, Ashlee, Pharm.D, Compounding Incidents Team Leader, FDA/CDER/OC/OU DLC - *nothing to disclose*
- La, Thang, PharmD, MPH, Central Triage Unit Manager, FDA/CDER/OSE/RSS - *nothing to disclose*
- Lucero, Karly, RN, DNP, MSN/eD, CCHP, Regional Field Medical Coordinator, DHS - *nothing to disclose*
- McClain, Rena, PharmD, CMS - *nothing to disclose*
- Nabavian, Sadaf, Senior Regulatory Project Manager, FDA - *nothing to disclose*
- Radden, Erica - *nothing to disclose*

CE Consultation and Accreditation Team

- Catherine Harrison, CE Consultant, FDA/CDER/OEP/DLOD - *nothing to disclose*
- Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - *nothing to disclose*

All of the relevant financial relationships listed for these individuals have been mitigated.

Registration Fee and Refunds

Registration is complimentary, therefore refunds are not applicable.